An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant.
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Bortezomib (Primary) ; Prednisolone; Thalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms VCAT
- Sponsors Janssen; Janssen-Cilag
- 07 Feb 2018 Status changed from active, no longer recruiting to completed.
- 17 Nov 2017 Planned End Date changed from 28 Feb 2018 to 25 Jan 2018.
- 15 May 2017 Planned End Date changed from 1 Jan 2018 to 28 Feb 2018.